<DOC>
	<DOCNO>NCT02476916</DOCNO>
	<brief_summary>Study AG348-C-003 multicenter study design evaluate safety efficacy different dose level AG-348 patient PK deficiency .</brief_summary>
	<brief_title>A Study AG-348 Adult Patients With Pyruvate Kinase Deficiency</brief_title>
	<detailed_description>This Phase 2 , open label , two arm , multicenter , randomize , dose-ranging study adult patient PK deficiency receive multiple dos AG-348 24 week ( Core Period ) ; eligible patient may enter Extension Period receive AG-348 2 additional year . Up 25 patient randomize two dos AG-348 ; third arm ( 25 patient ) may add , require . AG-348 administer orally various dos ; implement , dose Arm 3 determine base ongoing review . Data review regular basis study design , dose schedule adapt base review . The study evaluate safety tolerability multiple dose AG-348 , pharmacokinetic ( PK ) pharmacodynamic ( PD ) profile AG-348 early indicator clinical efficacy .</detailed_description>
	<mesh_term>Anemia , Hemolytic , Congenital Nonspherocytic</mesh_term>
	<mesh_term>Pyruvate Metabolism , Inborn Errors</mesh_term>
	<criteria>1 . Informed consent 2 . Male female , age 18 year old 3 . Known medical history PK deficiency 4 . PK deficiency confirm enzymatic assay Screening 5 . Genotypic characterization PKR gene Screening 6 . Genotypic characterization uridine5'diphosphateglucuronyltransferaseA1 ( UGTA1 ) gene document underlie Gilbert 's disease ( Gilbert 's disease pt eligible ) 7 . Males Hb ≤ 12.0 g/dL , females Hb ≤ 11 g/dL 8 . Transfusion independent , define 3 unit red blood cell ( RBC ) transfuse 12 month prior first day study dose transfusion within 4 month first day study dose 9 . Splenectomized patient must procedure least 6 month prior Screening must uptodate recommended vaccination 10 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 11 . Must take least 1 mg folic acid daily 21 day prior screen 12 . Adequate organ function define liver function , kidney function , platelet count coagulation assessments 13 . Agreement use approve contraceptive measure 14 . Women must breastfeed For entry Extension Period , patient must meet criterion # 1516 : 15 . Must complete 24 week treatment Core Period tolerate AG348 16 . The treat Investigator agree potential clinical benefit continue treatment recommend participation Extension Period Medical Monitor approve Exclusion criterion 1 . Hb ˃ 12.0 g/dL male , Hb ˃11.0 g/dL female 2 . Additional diagnosis congenital acquire blood disorder 3 . Iron overload sufficiently severe result cardiac , hepatic pancreatic insufficiency 4 . Bone marrow stem cell transplant 5 . Clinically symptomatic cholelithiasis cholecystitis 6 . Currently enrol investigational trial . Participation PK Deficiency Natural History Study ( NCT02053480 ) permit 7 . Exposure investigational drug , device procedure within 28 day prior screen trial participation 8 . Concurrent medical condition poorly control hypertension , heart failure , active infection , frequent postsplenectomy sepsis , Hepatitis B C , Human Immunodeficiency Virus type 1 ( HIV1 ) Human Immunodeficiency Virus type 2 ( HIV2 ) infection , poorly control diabetes mellitus , history primary malignancy exception curatively treat nonmelanomatous skin cancer , cervical cancer breast cancer situ 9 . Major surgery last 6 month 10 . Psychiatric disorder could compromise ability patient cooperate study 11 . Serum bilirubin high upper limit normal attributable factor hemolysis Gilbert 's Syndrome 12 . Use restricted product know strongly inhibit cytochrome P450 ( CYP ) 3A4 metabolism within 5 day prior Prior Day 1 dosing , strongly induce cytochrome P450 3A4 ( CYP3A4 ) metabolism within 28 day prior Day 1 dosing , strongly inhibit Pglycoprotein transporter within 5 day prior Day 1 dosing , digoxin within 5 day prior Day 1 dosing . 13 . Heartrate correct QT interval Fridericia 's method ( QTcF ) interval ˃ 450 m male , QTcF &gt; 470 m female , exception patient leave Bundle Branch Block 14 . Cardiac arrhythmia clinically significant treat drug substrates CYP3A4 15 . Allergy sulfonamide characterize acute hemolytic anemia , anaphylaxis , rash erythema multiforme type StevensJohnson Syndrome 16 . Any medical psychological condition deem Investigator likely interfere patient 's ability participate study 17 . Patients permit enter Extension Period : The patient experience AEs Core Period consider treat Investigator Sponsor 's designated Medical Monitor pose significant safety risk patient treatment extend</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pyruvate Kinase Deficiency</keyword>
	<keyword>Hemolytic anemia</keyword>
	<keyword>Protein Kinase R ( PKR )</keyword>
	<keyword>Drive PK</keyword>
</DOC>